Pfizer (PFE) R&D In Process (2009 - 2026)

Pfizer (PFE) has 9 years of R&D In Process data on file, last reported at $137.0 million in Q1 2026.

• Quarterly R&D In Process rose 1422.22% year-over-year to $137.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.7 billion (up 6117.86% YoY) and the FY2025 annual result came in at $1.6 billion, up 1393.52% from the prior year.
• R&D In Process fell to $137.0 million in Q1 2026 per PFE's latest filing, from $212.0 million in the prior quarter.
• Across five years, R&D In Process topped out at $1.4 billion in Q3 2025 and bottomed at $1.0 million in Q3 2022.
• The 5-year median for R&D In Process is $50.0 million (2023), against an average of $203.0 million.
• The widest annual swing landed in 2022, when R&D In Process sank 99.54%; it then soared 10592.31% in 2025.
• Tracing PFE's R&D In Process over 5 years: stood at $524.0 million in 2022, then slumped by 86.26% to $72.0 million in 2023, then plunged by 81.94% to $13.0 million in 2024, then soared by 1530.77% to $212.0 million in 2025, then plunged by 35.38% to $137.0 million in 2026.
• Per Business Quant, the three latest PFE R&D In Process figures stand at $137.0 million (Q1 2026), $212.0 million (Q4 2025), and $1.4 billion (Q3 2025).

Peer Comparison